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Abstract
Hematopoiesis is a complex process regulated by both cell intrinsic and cell extrinsic factors. Alterations in the expression of
critical genes during hematopoiesis can modify the balance between stem cell differentiation and proliferation, and may
ultimately give rise to leukemia and other diseases. AF10 is a transcription factor that has been implicated in the
development of leukemia following chromosomal rearrangements between the AF10 gene and one of at least two other
genes, MLL and CALM. The link between AF10 and leukemia, together with the known interactions between AF10 and
hematopoietic regulators, suggests that AF10 may be important in hematopoiesis and in leukemic transformation. Here we
show that AF10 is important for proper hematopoietic differentiation. The induction of hematopoietic differentiation in
both human hematopoietic cell lines and murine total bone marrow cells triggers a decrease of AF10 mRNA and protein
levels, particularly in stem cells and multipotent progenitors. Gain- and loss-of-function studies demonstrate that over- or
under-expression of AF10 leads to apoptotic cell death in stem cells and multipotent progenitors. We conclude that AF10
plays a key role in the maintenance of multipotent hematopoietic cells.
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Introduction
In adult vertebrates, hematopoiesis takes place in the bone
marrow starting with the integration of signals originated by cells
located in the hematopoietic stem cell (HSC) environment, known
as the HSC niche. These surrounding cells secrete specific
molecules, such as cytokines and chemokines, that initiate and
promote stem cell proliferation and differentiation and provide an
extracellular matrix that serves as an anchoring point for adhesion
of HSCs [1]. Daughter cells generated from HSCs can either
retain their self-renewal capability or may become committed to a
cell lineage and subsequently undergo terminal differentiation
[1,2]. Upon the integration of extracellular signals, the expression
of key genes in immature hematopoietic cells is modified,
switching on specific pathways that result in the change of the
characteristics of the cells [3,4]. Aberrant expression of these key
genes during hematopoiesis may lead to the development of
different hematological diseases, such as leukemia [5].
Chromosomal rearrangement of genes encoding transcription
factors with important roles during hematopoiesis are frequently
associated with leukemic processes [6]. One such frequently-
rearranged genes is MLL (Mixed Lineage Leukemia), located at
11q23, which encodes a highly conserved transcription factor
belonging to the Trithorax family of transcriptional activators [7].
MLL has been characterized as a major regulator of the homeotic
group of genes (Hox genes) [7] as well as a key controller of
hematopoiesis [8,9,10]. MLL is implicated in at least 70 different
chromosomal translocations associated with the development of
both infant and adult leukemias [11,12,13,14,15]. However,
despite the broad range of partners, 85% of the described
translocations involve rearrangements that affect just six genes:
AF4, AF9, ENL, AF6, AF10 and ELL, which have been suggested to
participate, together with MLL, in the same transcriptional
regulator complex [15]. The AF10 gene, located at 10p12, is the
only one of these six MLL recurrent partners that has been found
to participate in another leukemic translocation with the CALM
gene (Clatrhin-Assembly Lymphoid-Myeloid) [16,17], located at
11q14. CALM (also known as PICALM) is a cytoplasmic protein
implicated in endocytosis [18]. The translocation t(10;11)(p12;q23)
produces the MLL-AF10 fusion protein which is almost exclusively
found in patients with acute myeloid leukemia [19]. Translocation
t(10;11)(p12;q14) leads to the CALM-AF10 fusion protein, which
is present in patients with acute myeloid or acute lymphoid
leukemia [16]. Although AF10’s target genes remain unknown, its
implication in the development of myeloid, lymphoid and
megakaryoblastic leukemia upon translocation with either MLL
or CALM [16,17] suggests that AF10 may be an important factor
in the development of leukemia.
Although the molecular mechanisms through which AF10
influence the development of leukemia remain poorly understood,
some regions of AF10, important for leukemic transformation,
have been identified. In its C-terminal region, AF10 possesses an
octapeptide motif followed by a leucine zipper domain (OM-LZ,
Figure S1) implicated in its interaction with several proteins,
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including DOT1L [20,21]. Molecular analyses of MLL- and
CALM-AF10 rearrangements show differences in the location of
AF10 breakpoints, but the OM-LZ domain is present in both
fusion proteins (Figure S1) [16,17,20,21]. Furthermore, Desh-
pande et al showed recently that the fusion between the clathrin
binding domain from CALM and the OM-LZ from AF10 is
sufficient to induce acute myeloid leukemia in mice [22]. DOT1L
is a H3K79 histone-methyltransferase whose binding with AF10
modifies and activates the methylation pattern of the lysine 79 at
histone H3 tails on target gene promoters [20,21]. In the presence
of MLL- or CALM-AF10 fusion proteins, aberrant increases in the
expression level of genes such as HoxA5, HoxA7, HoxA9, HoxA10
and Meis1 have been described; all of these genes are involved in
hematopoiesis [23]. AF10 has also been shown to interact with
FLRG and Ikaros, both of which have been implicated in
hematopoiesis [24,25,26]. FLRG participates in erythrocytic
commitment, whereas Ikaros interacts with chromatin remodeling
factors and plays a role in transcriptional regulation and cell cycle
control during lymphocyte differentiation [27,28,29,30]. AF10 was
recently shown to be present in a complex also containing Tcf4/b-
catenin and Dot1L in mouse small intestinal crypts, zebrafish, and
Drosophila, where it participates in the maintenance of intestinal
cell homeostasis [31,32]. These data, together with the fact that
AF10 interacts with other proteins implicated in the hematopoietic
differentiation and its involvement in leukemic transformation
[16,17], suggest that AF10 has an important role in the regulation
of cell proliferation and differentiation in several tissues.
We sought to further investigate the role of AF10 in
hematopoiesis and leukemic transformation by testing the
consequences of AF10 gain- or loss-of-function during hemato-
poietic differentiation. We utilized four different human cell lines
(HEL, K562, CMK and HL-60) with the ability to differentiate
through diverse hematopoietic pathways as well as immature
primary hematopoietic stem cells obtained from mouse bone
marrow to test the effects of modulating AF10 function. HEL cells
follow either the megakaryocytic or the monocytic pathway,
depending on the concentration of 12-O-tetradecanoylphorbol 13-
acetate (TPA) used [33]. K562 and CMK cells are committed to
the megakaryocytic lineage [34,35], while HL60 cells follow the
monocytic lineage [36]. The induction of differentiation in all four
cells lines led to a decrease in both AF10mRNA and protein levels.
Small variations in AF10 gene expression induced apoptosis in
HEL cells, the only one of the cell lines used capable to
differentiate into diverse hematopoietic cell fates, but this effect
was not observed in the cell lines with committed fate. Mouse bone
marrow-derived immature hematopoietic cells show high AF10
expression levels, whereas these levels are very low in differentiated
macrophages, recapitulating our observations in immortalized cell
lines. Taken together, these data support the conclusion that AF10
plays an important role in the early stages of hematopoiesis but not
in differentiated stages. These results provide insight into AF10
function during hematopoiesis and contribute to a better
understanding of its role in leukemic transformation.
Methods
All experiments were assayed in triplicates in at least three
independent experiments. Figures show one representative inde-
pendent experiment.
Ethics statement
Mice used in the project were maintained according to the law
(R.D. 1201/2005, October 10th, BOE, October 21st, 2005) and
housed in the animal facility of UAM, Register number ES-28079-
0000097, and approved by the Ethical committee for Research
from the Universidad Autonoma de Madrid (Certificate Code
C13–201). Mice were sacrificed with CO2 followed by cervical
dislocation, a method that has been authorized by DG XI
European Commission 2010/63/UE, published 22 September
2010, annex IV.
Isolation of mouse primary cells from bone marrow
Bone marrow cells from 2–3 month-old CD1 mice were isolated
by flushing the femurs and tibias with complete RPMI 1640
medium. Cells were filtered to obtain a single cell suspension,
centrifuged at 1,000 RPM and cultured with complete RPMI
1640 medium at 37uC and 5% CO2. After 24 hours, cells were
incubated in complete RPMI 1640 medium supplemented with
30% monocyte colony stimulation factor (M-CSF) for 7 days at
37uC and 5% CO2 to induce monocytic differentiation. M-CSF
was obtained from the culture of L929 as described by Boltz-
Nitulescu and collaborators [37]. Briefly, L929 cells were
incubated with DMEM medium (Gibco) supplemented with
10% FBS (Gibco), 1% L-glutamine (Gibco) and 50 mg/ml
gentamicine (Normon Laboratories S.A). Medium was changed
when L929 cells were 90% confluent. After 72 hours with fresh
media, medium was collected, filtered and kept frozen until use.
The cell line L929 was a gift from Dr. Susana Alemany and its
original source was ATCC.
Cell culture and cell transfection
The cell lines HEL, K562, CMK and HL60 were grown in
complete RPMI 1640 medium (RPMI 1640 medium (Invitrogen)
supplemented with 10% FBS (Invitrogen), 1% L-glutamine
(Invitrogen) and 50 mg/ml gentamicin (Normon Laboratories
S.A)) at 37uC and 5% CO2. To induce megakaryocytic
differentiation in HEL, K562 and CMK cells and monocytic
differentiation in HL60 cells, cells were treated with 10 nM TPA
(Sigma Aldrich) for 72 hours [33,34,35,36]. HEL cells were
differentiated through the monocytic pathway with 1 mM TPA for
72 hours [33]. For the inhibition of the proteosome, the HEL cell
line was treated with 10 nM TPA during 24 h. After that period,
the cells were exposed to 10 nM MG132 or DMSO (vehicle)
together with the initial TPA treatment for 24 h more. For
transient transfections, 106 cells were transfected by nucleofection
with the AmaxaH Cell Line NucleofectorH Kit V (Lonza)
according to manufacturer’s protocol in the NucleofectorH
machine. Cells were cultured in complete RPMI 1640 medium
with or without TPA (depending on the assay) at 37uC and 5%
CO2 for 18 hours prior to their analysis. Cell lines HEL and K562
were kindly provided by Dr. Carmela Cale´s while CMK and
HL60 were gifts from Dr. Miguel Angel Piris. The original source
of these cell lines was ATCC.
Quantitative RT-PCR analysis
Total RNA from cells was isolated with TrizolH Reagent
(Invitrogen). The Quantitech Reverse Transcription Kit (Qiagen)
was used for cDNA synthesis, according to the manufacturer
protocol. Taqman Universal PCR Master Mix (Applied Biosys-
tems) was used for q-RT-PCR to analyze AF10 cDNA. The
specific probes (Applied Biosystems) were Hs00946024_m1 for
human AF10 cDNA and Mm00487708_m1 for mouse AF10
cDNA, and were used according to the manufacturer’s recom-
mendations. AF10 expression was calculated for each cell type
relative to 18S rRNA (Euk 18S rRNA) levels. The same 18S
rRNA probe was used for human and mouse analyses.
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Western blot
56105 cells were lysed with 50 ml of lysis buffer (25 mM Tris-
HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycho-
late, 0.1% SDS and protease inhibitors) for 10 minutes on ice and
centrifuged at 10,000 rpm for 10 min at 4uC. Protein concentra-
tion was measured with Dc Protein assay kit (Bio-Rad). 20 mg of
protein were separated by SDS-PAGE electrophoresis and
transferred to an Immobilon-PVDF membrane (Millipore). AF10
protein was detected with the monoclonal anti-AF10m (1:1000;
Abcam) or the polyclonal antibody anti-AF10p generated in the
laboratory (1:5000). Anti-TBP (1:2000; Santa Cruz Biotechnology)
was used as a control.
Immunofluorescence
Cells adhered to coverslips coated with 20 mg/ml fibronectin
(Sigma Aldrich) were fixed with 3.7% paraformaldehyde in PBS
for 15 minutes. Cells were washed twice with PBS for 5 minutes
and permeabilized and blocked in 5% Triton-X100 and 0.1 M
glycine in PBS. Fixed cells were incubated overnight at 4uC with
anti-AF10m antibody (1:1000). After two 5 minute washes in PBS,
cells were incubated with the appropriate secondary antibody for
1 hour in the dark and washed twice with PBS for 5 minutes.
Nuclei were stained with 1 mg/ml DAPI (Invitrogen). Images were
obtained using a Nikon Eclipse E400 microscope.
Flow cytometry
For all the protocols described in this section, 56105 cells were
washed with PBS and fixed with 10% formalin for 15 minutes in
ice unless otherwise indicated. For detection of phosphatidylserine,
cells were incubated with 3 ml of annexin V-DYE647 antibody
(Immunostep) in 100 ml annexin-V buffer (10 mM Hepes pH 7.4,
140 mMNaCl, 2.5 mM CaCl2) for 15 minutes at room temper-
ature in the dark. Annexin-V levels were determined as the
proportion of Annexin-V positive cells present in the total GFP
positive population. To detect the F4/80 or CD41 surface
markers, cells were incubated with 3 ml of F4/80 or CD41
antibody (Serotec) in 100 mL PBS for 15 minutes at room
temperature in the dark. For DNA content analyses, cells were
fixed with cold 70% ethanol and kept at 220uC during
30 minutes. Cells were incubated with 50 mg/ml propidium
iodide and 5 mg/ml RNAse in PBS. Cells were analyzed with a
Beckman Coulter-FC 500 MLP cytometer and the CXP software.
Constructs
For AF10 overexpression, KpnI and XbaI sites were terminally
added to AF10 coding sequence by PCR using appropriate
oligonucleotides. PCR products were then digested with both
enzymes and cloned in the pcDNA4/TO plasmid (Invitrogen).
GFP coding sequence was amplified from pStinger [38] and
cloned in to pcDNA4/TO plasmid following the same strategy.
This construct is referred to as GFP. To obtain the GFP-AF10
fusion protein-expressing construct, both cDNAs were amplified
by PCR so that the GFP 39 end overlaps with AF10 59 end. Then,
both fragments were used as bait in a second PCR round to obtain
the GFP-AF10 cDNA. This construct is referred to as GFP-AF10.
Sequences from these primers are available upon request. For
iRNA experiments, BLOCK-iTTMPOL II miRRNAi Expression
Vector Kit (Invitrogen) was used according to manufacturer’s
instructions. The scrambled control siRNA is referred to as
siControl. AF10 mRNA interfering constructs are referred to as
siAF10. Sequences from interfering harping are shown in Table
S1.
Statistical analyses
Data is presented as mean 6 SEM. A paired t-test was used to
determine the significance of the differences shown among
treatments. p,0.05 was considered statistically significant. Graph-
Pad Prism version 5.0 was used for statistical analyses.
Results
Expression pattern of AF10 during hematopoiesis
AF10 expression was assayed in vitro in a panel of four human
cell lines (HEL, K562, CMK and HL60) representing different
stages of hematopoietic differentiation. The HEL cell line, the
most uncommitted cell line in the panel, can differentiate into
megakaryocytes (when treated with 10 nM TPA) or into
monocytes (1 mM TPA) [33]. K562 and CMK cells can
differentiate into megakaryocytes and HL60 cells into monocytes
when they are treated with 10 nM TPA [34,35,36].
In order to determine the expression pattern of AF10 during
hematopoiesis, these four cell lines were induced to differentiate
down the megakaryocytic and/or monocytic pathways by
treatment with appropriate concentrations of TPA. At 72 hours
post induction, cell cycle and CD41 or F4/80 surface markers
levels were analyzed to confirm that the cells were differentiated
into megakaryocytes or monocytes, respectively (Figure S2). AF10
protein levels were analyzed by immunofluorescence microscopy
and western blot. When compared to the initial levels, both
analyses showed a reduction in AF10 protein levels after 72 hours
in the presence of TPA irrespective of the cell line or the
differentiation pathway (Figure 1A and S3). Intriguingly, HEL, the
most undifferentiated of the four cell lines, displayed the highest
basal levels of AF10 protein. In order to quantify this decrease,
AF10 levels were analyzed by flow cytometry before and after
incubation with TPA. As shown in Figure 1B, three of the four cell
lines showed a statistically significant (P,0.05) decrease in AF10
protein levels after the induction of differentiation, with the
reduction most apparent in the HEL cell line.
We next asked whether this decrease was due to an active
mechanism of protein degradation, to the down-regulation of
AF10 expression, or both. The inhibition of the proteasome
activity by its specific inhibitor MG123 after hematopoietic
differentiation in the HEL cell line led to the maintenance of
AF10 levels (Figure S4), indicating that there is an active
mechanism of degradation of AF10 upon differentiation. We also
analyzed the levels of AF10 mRNA by quantitative real-time RT-
PCR (qRT-PCR) before and after the differentiation induction. All
four cell lines showed a statistically significant reduction (P,0.05)
of mRNA amount after 72 hours of differentiation (Figure 1C).
Taken together, these data suggest that AF10 protein levels
decrease during hematopoietic differentiation and that this
decrease is likely due to the active degradation of the protein
through the proteasome and to the diminished AF10 gene
expression that results in a reduction in the steady state levels of
AF10 mRNA.
AF10 overexpression induces cell death in multipotent
hematopoietic cells
Since AF10 expression decreased during hematopoietic differ-
entiation, we next asked whether maintenance of proper AF10
mRNA and protein levels was important for this process. First, we
tested the effect of AF10 overexpression in stably transfected HEL
and K562 cell lines using a tetracycline-regulated promoter to
express AF10 or GFP-AF10 fusion proteins (data not shown). The
empty vector was used as a negative control. We obtained several
stable transfected clones for AF10, GFP-AF10 in the K562 cell line
AF10 and Hematopoiesis
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and the empty vector control in both cell lines. However, we were
unable to obtain any positive HEL clones expressing AF10 or
GFP-AF10 (data not shown). Since positive clones were obtained
using the empty vector in the HEL cell line, we reasoned that the
lack of HEL clones expressing either transfected AF10 or GFP-
AF10 could be due to low levels of AF10 expression due to the
known leakiness of the tetracycline inducible promoter. If this were
true, then one possible explanation for our inability to identify
stable AF10-HEL lines would be that even low levels of AF10
overexpression leads to cell death in the HEL line but not in K562.
To test this hypothesis, apoptosis levels were analyzed in all four
cell lines transiently transfected with GFP-AF10 or GFP (control).
Annexin-V was used as an early apoptotic marker and the GFP
signal was used to identify transfected cells. The transfection
efficiency varied between 30–75% depending on cell line used
(Figure S5). At 18 hours post-transfection, cells were incubated
with annexin-V and cell death was quantified by flow cytometry.
While no increase in the number of apoptotic cells was observed in
K562, HL60 or CMK expressing GFP or GFP-AF10, HEL cells
transfected with GFP-AF10 have a statistically significant increase
(P,0.01) of the number of annexin-V positive cells as compared to
the same cell line transfected with the GFP control (Figure 2A;
white bars). This result shows that overexpression of AF10 in HEL
cells, but not in any of the other cell lines tested, leads to apoptotic
cell death.
Since we found that differentiation leads to reduction of AF10
mRNA and protein levels (Figure 1), we next asked whether this
reduction was specific for the endogenous protein. To answer this
question, GFP and GFP-AF10 levels were analyzed by flow
cytometry in the four cell lines before and after TPA-induced
differentiation. As shown in Figure 2B, differentiation induction
results in a moderate decrease of relative GFP-AF10 signal in all
cell lines irrespective of the differentiation pathway analyzed.
GFP-AF10 protein level reduction is less apparent in the HEL cell
line. This might be due to the fact that HEL cells display the
highest basal AF10 expression levels, hence the decrease of AF10
levels requires longer periods than in the other cell lines. Since
transfected GFP-AF10 mRNA levels should not be affected by
Figure 1. Expression pattern analysis of AF10 protein during hematopoiesis. Detection of AF10 protein by western blot (A) and flow
cytometry (B) before (2) and after (+) the treatment with TPA of the cell lines HEL, K562 and CMK, for the megakaryocytic pathway (upper panels),
and HEL and HL60, for the monocytic pathway (bottom panels). (C) Relative quantification of the levels of AF10 mRNA by qRT-PCR before (2) and
after (+) treatment with TPA. Paired t-test; * P,0.05; ** P,0.01; *** P,0.001 (n$3).
doi:10.1371/journal.pone.0051626.g001
Figure 2. Effect of AF10 over-expression during hematopoiesis.
(A) Relative annexin-V in the cell lines transfected with GFP-AF10
plasmid before (2TPA) and after (+TPA) the induction of megakaryo-
cytic differentiation, in cells lines HEL, K562 and CMK, and monocytic
differentiation in cell lines HEL and HL60. Dashed line indicates the
annexin-V levels of the cells lines transfected with GFP plasmid
normalized to 1. (B) Flow cytometry analysis of GFP-AF10 protein levels
in all cell lines after the induction of megakaryocytic and monocytic
differentiation. Paired t-test; * P,0.05; ** P,0.01 (n$3).
doi:10.1371/journal.pone.0051626.g002
AF10 and Hematopoiesis
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differentiation induction, the observed decrease in GFP-AF10
protein levels must be mainly due to protein degradation, further
supporting the conclusion that induction of differentiation leads to
activation of the cellular machinery responsible for the reduction
of both AF10 mRNA and protein.
These results led us to predict that induction of differentiation
would not only cause a reduction in AF10 protein levels, but would
also prevent apoptosis in HEL cells resulting from GFP-AF10
overexpression. To test this hypothesis, we induced the transfected
cells to differentiate with TPA down the megakaryocytic and/or
monocytic pathway. 18 hours after TPA treatment, apoptosis
levels were analyzed by flow cytometry. Induction of differentia-
tion after transfection caused a strong reduction in the number of
apoptotic HEL cells irrespective of whether the differentiation
pathway followed is megakaryocytic or monocytic (P,0.05)
(Figure 2A; black bars). As expected, no changes in annexin-V
levels were observed after differentiation induction in any of the
other cell lines analyzed. We infer that AF10 levels must be tightly
regulated during hematopoietic differentiation.
AF10 knockdown induces apoptosis in multipotential
cells
We next sought to analyze the consequences of reduction in
AF10 expression levels, reasoning that if each differentiation stage
requires a particular AF10 expression level, it is likely that a strong
decrease in AF10 expression might have adverse consequences.
Since AF10 expression was shown to be high in the less-committed
cells, we hypothesized that a large decrease in AF10 expression
would not be tolerated by uncommitted cells. In order to study the
effect of knocking down AF10 mRNA, an interference hairpin
(siAF10) and the scrambled control siRNA (siControl) were cloned
following the GFP cDNA. Since both sequences were expressed in
a single mRNA, the GFP signal was used to identify siAF10-
expressing cells.
Based in our findings in the overexpression assay, we sought to
determine if AF10 knockdown affected cell viability. The four cells
lines were transiently transfected with siAF10 and siControl
plasmids. 18 hours after transfection, cells were collected and
incubated with annexin-V and apoptosis levels measured by flow
cytometry. As shown in figure 3A for HEL and K562 cell lines,
similar levels of knockdown were achieved in both cell lines. Since
cells were transiently transfected and transfection efficiency was
estimated between 40 and 80% depending on the cell line (Figure
S6), we concluded that the knockdown was effective in the
transfected cells. We found that AF10 knockdown in undifferen-
tiated HEL cells led to a significant increase in the number of
apoptotic cells (Figure 3B). In contrast, no significant increase was
observed in any of the more committed cell lines. This result is in
accordance with our hypothesis that AF10 levels must be tightly
controlled throughout hematopoietic differentiation in not fully
committed cells.
To further confirm our hypothesis, we asked whether the
induction of differentiation prevented HEL cells from undergoing
apoptosis following AF10 knockdown. After transfection with
either siControl or siAF10, megakaryocytic and/or monocytic
differentiation was induced in all four cell lines by TPA treatment.
Differentiation of HEL cells into megakaryocytes or monocytes
resulted in a significant reduction in the number of apoptotic cells
as compared with uninduced HEL cells (P,0.05 and ,0.01
respectively; Figure 3B). No changes in apoptosis were observed in
any of the other cell lines upon differentiation.
Expression pattern of AF10 in primary cultures from
mouse bone marrow
The results presented above demonstrating that AF10 levels
must be tightly controlled through hematopoietic differentiation
led us to hypothesize that AF10 might play an essential role
throughout hematopoiesis in vivo. To address this question, we
performed an ex vivo analysis (as a surrogate of in vivo experiments)
of AF10 expression levels in primary mouse cells during the
differentiation process. Hematopoietic cells were isolated from
mouse bone marrow and cultured in the presence of M-CSF for 7
days to induce the monocytic pathway. Since F4/80 has been
described as a typical monocyte surface marker [39], it was used to
monitor the progress of monocytic differentiation induced in the
primary cultures. Figure 4A shows that incubation with medium
containing M-CSF for 7 days led to a 7-fold increase in F4/80
levels, confirming that monocytic differentiation occurred. To test
whether AF10 expression levels were regulated during the
monocytic differentiation pathway, AF10 mRNA and protein
levels were measured before and after induction of differentiation
using western blot and flow cytometric analyses. Primary
immature bone marrow cells showed high levels of AF10 protein.
In contrast, AF10 protein levels in differentiated monocytes were
barely detectable (Figure 4B). A quantitative analysis of AF10
protein expression by flow cytometry revealed a statistically
significant reduction (P= 0.001) in its expression in primary bone
marrow cells 7 days after induction of differentiation (Figure 4C).
We showed above that AF10 mRNA levels are strongly reduced in
differentiated cells irrespective of the differentiation pathway
studied (Figure 1D). To further investigate the relevance of these
data, we measured AF10 mRNA levels in primary bone marrow
cells and differentiated monocytes. AF10 expression was reduced
more than 90% after 7 days of differentiation, confirming that
AF10 expression is strongly regulated in primary cultures of
hematopoietic cells during the hematopoietic differentiation
(Figure 4D). In summary, our results demonstrate that AF10
Figure 3. Effect of AF10 loss-of-function during hematopoiesis.
(A) Western blot analysis of AF10 expression in HEL and K562 cell lines
transfected with scrambled siControl and siAF10. (B) Analysis of
annexin-V levels in cell lines transfected with scrambled siControl and
siAF10 before (2TPA) and after (+TPA) the induction of megakaryocytic
differentiation, in cell lines HEL, K562 and CMK, and monocytic
differentiation in cell lines HEL and HL60. Dashed line indicates the
annexin-V levels of the cells lines transfected with scrambled siControl
plasmid normalized to 1. Paired t-test; * P,0.05; ** P,0.01 (n$3).
doi:10.1371/journal.pone.0051626.g003
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expression is tightly regulated through hematopoietic differentia-
tion, suggesting that it plays an important role in the process.
Discussion
In this study, we examined the expression pattern of transcrip-
tion factor AF10 during hematopoietic differentiation through the
megakaryocytic and monocytic pathways. The in vitro assays
developed in the human hematopoietic cell lines HEL, K562,
CMK and HL60 showed a reduction of both AF10 protein and
mRNA levels during the progression of cell differentiation
(Figure 1-S3), suggesting an in vivo down regulation of AF10 in
the later stages of hematopoiesis. A detailed analysis of these results
revealed that the four cell lines used in this work (all of which are
at different stages of hematopoietic differentiation), expressed
different basal AF10 levels before differentiation. HEL, the most
‘‘uncommitted’’ cell line in our panel, expressed the most AF10
before differentiation (Figure S3). The AF10 abundance in the
other three undifferentiated cell lines correlates with their
respective commitment in the hematopoietic lineage (Figure S3).
Accordingly, the analysis of differentiated cells overexpressing
AF10 shows a distinct reduction in protein levels (Figure 2A). As
AF10 overexpression is driven by a viral promoter, and therefore is
not developmentally regulated, this result, together with mainte-
nance of AF10 protein levels in differentiated cells after
proteasome inhibition (Figure S4), shows that the decrease in
protein levels is likely due to active protein degradation, and not
just transcriptional down-regulation. This indicates that both AF10
gene silencing and active protein degradation mechanisms
contribute to its regulation. Taken together, these results suggest
that AF10 levels must be tightly regulated throughout hemato-
poietic differentiation. To determine whether the results obtained
in cell lines reflect the in vivo role of AF10, we analyzed AF10 in
primary cells. Monocytic differentiation was induced in immature
hematopoietic cells from mouse bone marrow and the levels of
both AF10 protein and mRNA were measured before and after
differentiation. We observed a strong reduction of AF10 protein
and mRNA (Figure 4), supporting the premise that AF10 plays
role during hematopoiesis in vivo.
Recent reports by Mahmoudi et al. and Mohan et al. showed that in
mice, zebrafish and Drosophila, Dot1L, Tcf4/b-catenin and AF10
form a stable complex along with several other proteins [31,32].
Dot1L is a well-characterized histone methyltransferase whose
interaction with AF10 has long been established [20]. Although
there are no in vivo data available on the role of AF10 during
hematopoiesis, it has been recently shown that Dot1L2/2 mice and
embryonic stem cells have severe defects in hematopoietic
differentiation due to the block of cell-cycle progression which
promotes apoptosis of hematopoietic progenitor cells [40,41]. b-
catenin is key in the Wnt pathway, which serves a critical role in
tissue development, progenitor cell proliferation, and many
human cancers [42]. Canonical Wnt signaling is considered to
be an important pathway for maintaining or inducing an
undifferentiated phenotype in HSCs [43,44]. Therefore, over-
expression of Wnt signaling components can potentially enhance
HSC self-renewal. In contrast, loss of canonical Wnt signaling may
lead to impaired self-renewal, showing that maintenance of Wnt
signaling at the exact dose is critical for HSC function [42]. This
pathway has also been shown to regulate apoptosis in many tissues,
and activation of canonical Wnt signaling has been associated with
either a decrease or increase in apoptosis [45,46]. Considering this
information, the presence of Tcf4/b-catenin in the AF10-Dot1L
complex also supports an in vivo role of AF10 during hematopoietic
differentiation.
In agreement with these observations, the data obtained from
the AF10 gain and loss of function experiments show that these
alterations induce cell death by apoptosis in the more uncommit-
ted cell line HEL, but not in any of the other cell lines analyzed
(Figures 2–3). Moreover, induction of differentiation in HEL cells
rescues cell death induced by both AF10 over-expression or
knockdown (Figures 2B–3B). Considering that HEL cells are the
only cells used in these experiments that maintain multipotential
characteristics, these results indicate that the alteration of AF10
levels compromises the viability of uncommitted cells. According-
ly, the loss of uncommitted cell properties due to the differentiation
process prevents cell death induction by changes in AF10 levels
(Figures 3A–4A). Since the catalytic properties of Dot1L are
regulated in vivo by AF10 [32], it is key that Dot1L2/2 embryonic
stem cells present elevated apoptosis levels and G2 cell cycle arrest
Figure 4. Expression pattern of AF10 in mice bone marrow-derived cells. (A) Quantification of relative F4/80 surface surface expression by
flow cytometry before (T0) and after (T7) the cellular differentiation. (B–C) Immunodetection of the protein AF10 by western blot and flow cytometry,
respectively, in cells extracted from bone marrow before (T0) and after (T7) the induction of cell differentiation. (D) Quantification by qRT-PCR of the
relative levels of AF10 mRNA before (T0) and after (T7) the differentiation of the cells. Paired t-test; *** P,0.001 (n$3).
doi:10.1371/journal.pone.0051626.g004
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in hematopoietic progenitor cells [41,47]. These data agree with
gene expression studies showing that in Dot1L2/2 cells, gene
ontology groups related to cell proliferation, cell cycle progression,
and apoptosis are statistically overrepresented in a list of
differentially expressed RNAs [48]. Taken together, these results
support our hypothesis that precise control of AF10 levels is crucial
in early stages of hematopoiesis.
In conclusion, we have demonstrated the significance of AF10
during the uncommitted stages of hematopoiesis, as well as the
importance of AF10 maintenance at these stages. Based on these
findings, we infer that AF10 could be directly or indirectly
implicated in cell cycle regulation. Changes in expression levels
leads to apoptosis only in the multipotential cells, which retain
proliferative capacity. AF10’s interaction with Ikaros, a protein
involved in lymphocyte cell cycle control [26,29], as well as with
Dot1L and b-catenin, both of which are involved in the regulation
of apoptosis and hematopoiesis [32], supports our findings.
Although further investigation is needed to reveal the molecular
mechanisms of AF10 action during hematopoiesis, our data
demonstrate that AF10 participates in the early stages of
hematopoiesis and contribute to a better understanding of the
link between the translocation of AF10 and the development of
lymphoid and myeloid proliferative diseases.
Supporting Information
Figure S1 Schematic representation of protein struc-
tures and model system. Schematic representation of
AF10, MLL-AF10 and CALM-AF10 structure. Arrows show
the break points in AF10 when the chromosomal rearrangements
occur. OM: octapeptide motif; LZ: leucine zipper.
(TIF)
Figure S2 Cell line differentiation. (A) DNA content in
HEL, K562, CMK and HL60 cell lines before and after
TPA treatment for the induction of megakaryocytic
(upper panels) or monocytic (bottom panels) differenti-
ation. (B) Levels of specific markers of megakaryocytic (CD41)
and monocytic (F4/80) differentiation before and after the
exposure to TPA. Paired t-test; * P,0.05; ** P,0.01 (n$3).
(TIF)
Figure S3 Immunohistochemistry. AF10 immunodetection
(green) in the cell lines HEL, K562, CMK and HL60 before
(2TPA) and after (+TPA) megakaryocytic (A) or monocytic (B)
differentiation. DNA was stained with DAPI (blue).
(TIF)
Figure S4 Inhibition of the proteasome activity during
differentiation. Western blot analyses of AF10 levels in the cell
line HEL. Cells were incubated with TPA for 24 h followed by
24 h of treatment with the specific proteasome inhibitor MG132
or DMSO (vehicle). AF10 analyses were performed in cells
exposed to DMSO (1st lane), to TPA during 24 h or 48 with TPA
(2nd and 3rd lanes respectively) and 48 h with TPA and the last
24 h also with MG123 (4th lane). AF10 was detected with antibody
anti-AF10m and TBP was used as loading control.
(TIF)
Figure S5 Overexpression efficiency determination by
flow cytometry. Untransfected cells (left panels) were assayed to
determine the threshold for GFP detection. Cells transfected with
GFP and GFP-AF10 plasmids were analyzed to determine the
transfection efficiency. Percentages indicate the percentage of GFP
positive cells.
(TIF)
Figure S6 Determination of knockdown efficiency by
flow cytometry. Untransfected cells (left panels) were assayed to
determine the threshold for GFP detection. GFP signal after
transfection with siControl or siAF10 plasmids represents the
transfected population. Percentages indicate the percentage of
GFP positive cells.
(TIF)
Table S1 Oligonucleotides sequences used for AF10
knock-down. In red, complementary regions that will generate
the dsRNA. The underlined sequence indicates the sequence that
will recognize AF10 mRNA region that will activate the dsRNA
degradation machinery. siAF10, interference plasmid; siControl,
control plasmid with no homology to any known vertebrate DNA
sequence.
(XLSX)
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